D.E. Shaw & Co’s SQZ Biotechnologies Company SQZ Stock Holding History

D.E. Shaw & Co’s Portfolio SQZ Stock Details SQZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,593	Closed	-$227K	–	5112
2021 Q1	$227K	Buy	+16,593	New	+$337K	﹤0.01%	3809

Other funds holding SQZ

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's SQZ Position: Q2 2021 in Review

D.E. Shaw & Co sold out of SQZ Biotechnologies Company (SQZ) in Q2 2021, closing a stake of 16,593 shares — an estimated $227K sold.

D.E. Shaw & Co first reported a position in SQZ in Q1 2021 and held it in 1 quarter. The position peaked at $227K in Q1 2021. 49 funds tracked by Wall St. Rank hold SQZ as of Q2 2021.

D.E. Shaw & Co reported no remaining SQZ Biotechnologies Company position as of Q2 2021 after selling out during the quarter.
D.E. Shaw & Co sold 16,593 SQZ Biotechnologies Company shares in Q2 2021, an estimated $227K.
D.E. Shaw & Co first reported a position in SQZ Biotechnologies Company in Q1 2021 and held it in 1 quarter.
D.E. Shaw & Co's SQZ Biotechnologies Company position peaked at $227K in Q1 2021.
49 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q2 2021.

Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.